ENDRA Life Sciences Inc (NDRA) USD0.0001
- Add to watchlist
- This stock can be held in a
Business summary
ENDRA Life Sciences Inc. develops technology for increasing the capabilities of clinical diagnostic ultrasound to broaden patient access to the diagnosis and treatment of various medical conditions in circumstances where other diagnostic technologies are unavailable or impractical. The Company has developed a technology platform, Thermo Acoustic Enhanced Ultrasound (TAEUS), which is intended to enhance the capability of clinical ultrasound technology and support the diagnosis and treatment of various other medical conditions. Its TAEUS technology platform application focuses on quantifying fat in the liver and staging the progression of non-alcoholic fatty liver disease (NAFLD), which, if untreated, can progress to non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and liver cancer. The Company's TAEUS platform has various clinical applications, such as tissue composition, temperature monitoring, vascular imaging, and tissue perfusion.
Contact details
Important dates
General stock information
- Short code:
- NDRA
- ISIN:
- US29273B3024
- Market cap:
- $6.94 million
- Shares in issue:
- 8.45 million
- Sector:
- Health Care Equipment
- Exchange:
- NASDAQ
- Country:
- United States
- Currency:
- US dollar
- Indices:
- n/a
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.